EMEA-002559-PIP04-21

Table of contents

Key facts

Active substance
Anti-neonatal Fc receptor human monoclonal antibody
Therapeutic area
Neurology
Decision number
P/0419/2021
PIP number
EMEA-002559-PIP04-21
Pharmaceutical form(s)
Solution for infusion
Condition(s) / indication(s)
Treatment of chronic inflammatory demyelinating polyradiculo-neuropathy
Route(s) of administration
Intravenous use
Contact for public enquiries
Janssen-Cilag International NV

E-mail: contact@janssen-emea.com
Tel.: + +32 473112810

Decision type
W: decision granting a waiver in all age groups for all conditions or indications

Decision

How useful was this page?

Add your rating